论文部分内容阅读
目的:前列地尔联合贝那普利治疗糖尿病肾病的价值。方法:收集我院糖尿病肾病蛋白尿患者,分为:研究组和对照组。两组均接受贝那普利降压、降脂、降糖等,研究组加用前列地尔治疗。对比对比两组治疗前后24h尿蛋白含量及24h尿微白蛋白排泄率。结果:两组治疗前24h尿蛋白含量及24h尿微白蛋白排泄率比较无差异(P>0.05);两组治疗后24h尿蛋白含量及24h尿微白蛋白排泄率比较有差异(P<0.05)。结论:前列地尔联合贝那普利治疗糖尿病肾病引起的蛋白尿疗效肯定。
Purpose: The value of alprostadil combined with benazepril in the treatment of diabetic nephropathy. Methods: Patients with diabetic nephropathy proteinuria were collected and divided into study group and control group. Both groups received benazepril antihypertensive, lipid-lowering, hypoglycemic, etc., the study group plus alprostadil treatment. The levels of urinary protein and 24h urinary albumin excretion before and after treatment were compared between two groups. Results: There was no significant difference in 24h urinary protein and 24h urinary albumin excretion before and after treatment (P> 0.05) ). Conclusion: Alprostadil combined with benazepril is effective in treating proteinuria caused by diabetic nephropathy.